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Background. Women infected with human immunodeficiency virus (HIV) are disproportionately affected by
human papillomavirus (HPV)–related anogenital disease, particularly with increased immunosuppression. AIDS
Clinical Trials Group protocol A5240 was a trial of 319 HIV-infected women in the United States, Brazil, and
South Africa to determine immunogenicity and safety of the quadrivalent HPV vaccine in 3 strata based on screening
CD4 count: >350 (stratum A), 201–350 (stratum B), and ≤200 cells/µL (stratum C).
Methods. Safety and serostatus of HPV types 6, 11, 16, and 18 were examined. HPV serological testing was per-
formed using competitive Luminex immunoassay (HPV-4 cLIA). HPV type-specific seroconversion analysis was
done for participants who were seronegative for the given type at baseline.
Results. Median age of patients was 36 years; 11% were white, 56% black, and 31% Hispanic. Median CD4 count
was 310 cells/µL, and 40% had undetectable HIV-1 load. No safety issues were identified. Seroconversion propor-
tions among women at week 28 for HPV types 6, 11,16, and 18 were 96%, 98%, 99%, and 91%, respectively, for
stratum A; 100%, 98%, 98%, and 85%, respectively, for stratum B, and 84%, 92%, 93%, and 75%, respectively, for
stratum C.
Conclusions. The quadrivalent HPV vaccine targeted at types 6, 11, 16, and 18 was safe and immunogenic
in HIV-infected women aged 13–45 years. Women with HIV RNA load >10 000 copies/mL and/or CD4 count
<200 cells/µL had lower rates of seroconversion rates.
Clinical Trials Registration. NCT00604175.
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Persistent infection with oncogenic human papilloma-
virus (HPV) can cause anal and cervical intraepithelial
neoplasia and cancer [1, 2]. Human immunodeficiency
virus (HIV)–infected women are disproportionately af-
fected by HPV-related anogenital disease, compared
with HIV-uninfected women [3, 4]. Despite the immu-
nologic reconstitution associated with the use of combi-
nation antiretroviral therapy (cART), the prevalence of
anogenital HPV infections and diseases remains high
[5–7]. Current cervical cancer prevention strategies are
aimed at secondary preventions with early detection
and treatment of intraepithelial lesions due to HPV
infection, and to date there is no consensus in the
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literature on how to implement anal cancer prevention among
women. These measures may not be accessible to women living
in countries with limited medical resources, areas that carry a
disproportionate mortality burden from cervical cancer [8]. Pri-
mary prevention of HPV infection is therefore critically needed.
The quadrivalent HPV vaccine was designed to prevent 4
types of HPV infection, types 16 and 18 (the causative agents
of most cervical and anal cancers) and types 6 and 11 (which
cause most anogenital warts). The vaccine consists of virus-
like particles generated by the expression of the major capsid
protein L1 from HPV types 6, 11, 16, and 18 with an aluminum
adjuvant. When given to HIV-uninfected women without prior
exposure to HPV-16 or -18, the HPV vaccine demonstrated
98% efficacy in preventing cervical intraepithelial neoplasia re-
lated to the vaccine types [9] and 100% of anogenital warts [10].
In a trial of healthy boys and men 16–26 years of age, the effi-
cacy of the vaccine was 90.4% in preventing external genital le-
sions due to the vaccine types [11]; among 602 men who have
sex with men, the efficacy against anal intraepithelial neoplasia
associated with the vaccine types was 77.5% [12]. The use of the
vaccine among 700 black women prevented 100% of cervical
and vulvar disease [13]. To our knowledge, no vaccine efficacy
studies have been published to date on HIV-infected persons.
HIV-infected persons have been documented to have poor
responses to standard vaccination series such as hepatitis A
and B [14–16]. Data on predictors of immunogenic responses
to vaccinations have been inconsistent, but both HIV viremia
and CD4 cell counts can affect responses [14, 17]. In a study de-
signed to assess the immunogenicity of the quadrivalent HPV
vaccine among HIV-infected men with CD4 cell counts
>200 cells/µL, 95% exhibited seroconversion and no relationship
between CD4 cell counts and HPV antibody concentrations
were observed, but higher anti–HPV-16 and -18 antibody con-
centrations were noted in those receiving cART [18]. Similar re-
sults were found among 99 HIV-infected young women aged
16–23 years [19]. Neither study included participants with
CD4 cell counts <200 cells/µL. Here we present data on the
first 28 weeks on study from an international multicenter clin-
ical trial that aimed to assess the immunogenicity and safety of
the quadrivalent HPV vaccine among HIV-infected women
aged 13–45 years with different levels of CD4 cell counts.
METHODS
Study Design
AIDS Clinical Trials Group (ACTG) Protocol 5240 (see Appen-
dix for group members) was an international phase 2, open-
label, single-arm study with stratification by CD4+ cell count
to assess the immunogenicity and safety of the quadrivalent
HPV recombinant vaccine (Gardasil) directed against HPV
types 6, 11, 16, and 18. CD4 cell strata were defined as stratum
A: >350 cells/µL; stratum B: 201–350 cells/µL, and stratum C:
≤200 cells/µL. The 3 strata opened simultaneously. The study
initially had HIV RNA stratification to balance the number of
participants with ≤10 000 copies/mL in each CD4 stratum. This
stratification was subsequently removed due to enrollment delay
as it was not a part of the primary study analysis. We planned to
analyze data using both the 10 000 and 400 copies/mL cutoffs,
as the latter may be clinically more meaningful. The primary
endpoint of the study was type-specific HPV antibody develop-
ment 1 month after the completion of the HPV vaccination se-
ries (week 28) in participants negative for the type-specific
antibodies at baseline. Seroconversion from seronegative to se-
ropositive status was defined as the development of antibody
levels above the serostatus cutoffs for HPV types 6, 11, 16,
and 18 as determined by the assay developer: ≥20, ≥16, ≥20,
and ≥24 milli-Merck units (mMU)/mL, respectively. The
planned sample size was 134 women in each of the 3 CD4
cell count strata. Participants were enrolled at ACTG sites in
the United States; Fiocruz, Brazil; and Johannesburg, South Af-
rica. Institutional review boards of the participating institutions
approved the study, and each participant gave written informed
consent.
The protocol was amended as new data emerged and to im-
prove feasibility. The sample size was adjusted to 94 participants
in each stratum based on seroconversion rates from external
HPV vaccine studies. Other changes to the protocol included
allowing women with prior cervical low-grade cytology results
to enroll and removal of ART duration requirement prior to the
study.
Enrollment Criteria
Inclusion criteria were follows: women aged 13–45 years; doc-
umentation of HIV type 1 (HIV-1) infection, hemoglobin level
≥8.0 g/dL, platelet count ≥100 000/µL, aspartate and alanine
aminotransferase levels ≤3 times the upper limit of normal
(ULN), direct bilirubin level of <2.5 × ULN, and a Karnofsky
score ≥70. Participants of reproductive potential were required
to use contraception for the duration of the study.
Individuals were excluded if they had high-grade cervical in-
traepithelial neoplasia (CIN II or III), vaginal intraepithelial
neoplasia (VIN II or III), or genital warts within 180 days
prior to study entry. Recent or expected use of systemic antineo-
plastic agents, immunomodulatory treatments, or investigation-
al vaccines was excluded. Women with known hypersensitivity
to components of the vaccine, currently pregnant or breastfeed-
ing, hemophilia, prior hysterectomy, or prior receipt of HPV
vaccines were excluded.
Study Treatment
At entry, week 8, and week 24, participants received the quad-
rivalent HPV vaccine 0.5 mL intramuscularly. The primary
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immunogenicity endpoint was determined 4 weeks after the
third vaccination.
Study Evaluations
We report on clinical assessments made at each vaccination
and at weeks 4, 12, and 28. CD4 cell count was assessed at
entry and weeks 4, 8, 12, 24, and 28. Plasma HIV-1 RNA and
routine laboratory monitoring were assessed at entry and weeks
4, 12, and 28. Participants were contacted 24–48 hours after each
vaccination to assess for vaccine-related symptoms. All laboratory
abnormalities, signs, and symptoms were graded using the Divi-
sion of AIDS Adverse Event Grading Table, Version 1.0.
Laboratory Testing
HPV serological testing was performed using competitive Lu-
minex immunoassay (HPV-4 cLIA; Merck Research Laborato-
ries). Anal and cervical HPV DNA polymerase chain reaction
(PCR) testing was performed with MY09/MY11 primers and
L1 consensus and type-specific probing as described elsewhere
[20].HIVRNA testingwas performed locally, usingRocheUltra-
Sensitive HIV Real-time (RT) PCR, Roche COBAS AmpliPrep/
TaqMan HIV-1, or Roche Amplicor Monitor HIV RT PCR.
Statistical Methods
The initial target sample size of 134 in each CD4 stratum was
based on the assumption of at least 70% true seroconversion
proportion for each HPV type, where the proportion greater
than the null of 50% was to be considered success in the
study population. With emerging results from completed
HPV vaccine studies in the literature, the sample size was sub-
sequently adjusted to 94 in each stratum, now assuming at least
90% true seroconversion proportion and to conclude propor-
tion greater than the revised null of 70% as success. These sam-
ple sizes accounted for loss to follow-up and exclusion of
individuals seropositive for all 4 HPV types at study entry
who would not contribute to the primary analysis.
The primary immunogenicity analysis was on participants
who had completed the vaccination series per protocol, had
HPV-negative antibody results at baseline, and available week
28 results. Analysis on all participants who received any vaccines
was conducted as an intention-to-treat, secondary analysis.
The proportion of type-specific antibody seroconversion
within each CD4 stratum was estimated with a 2-sided 95%
confidence interval (CI) using exact Clopper-Pearson method,
without adjustment for multiple CIs. The CIs around geometric
mean titers (GMTs) were calculated assuming t distribution of
log10-transformed antibody titer. Fisher exact tests were used to
compare binary or categorical variables among groups. A joint
model that includes all observed antibody results from each in-
dividual who was seronegative for all 4 HPV types at baseline
was developed, to assess the effects of HPV type, baseline
CD4 cell count (>200 or ≤200 cells/µL), baseline HIV RNA
level (>10 000 or ≤10 000 copies/mL), and age (>35 or ≤35
years) on seroconversion. The generalized estimating equation
(GEE) approach using a logit link function was taken as a meth-




Three hundred nineteen participants were enrolled from March
2008 to July 2011 (130 participants in stratum A, 95 in stratum
B, and 94 in stratum C). Accrual to strata A and B was complet-
ed prior to the sample size adjustment with enrollment exceed-
ing 94. There were 29 participants enrolled from Brazil and 25
from South Africa. One participant in stratum A was found to
be ineligible after enrollment; 2 participants in stratum A and 1
participant in stratum C were not able to start vaccination series
within 72 hours of entry and were removed from the study and
excluded from the analysis. Therefore, the total number of par-
ticipants in this analysis was 315, with 127 in stratum A, 95 in
stratum B, and 93 in stratum C. Baseline participant character-
istics are shown in Table 1. Baseline seropositivity for each of
the 4 HPV vaccine types is presented in Table 2. It ranged be-
tween 13% and 45%; only 4% of women were seropositive for all
4 types, with no difference among women with high or low
baseline CD4 counts. We did not find an association between
age and baseline seropositivity except for HPV type 18 in the
highest and lowest CD4 strata (P = .041 and .027, respectively).
There were no statistically significant differences in seropreva-
lences in the US sites and non-US sites across the 3 CD4 strata.
Cervical and/or anal HPV DNA results on types 6/11 (com-
bined), 16, and 18 were available for 287 subjects (115 in
CD4 stratum A, 86 each in B and C). Of the 146 subjects who
were seronegative for types 6/11 at baseline, 2 (1.4%) were DNA
positive. Of the 175 who were seronegative for type 16 at base-
line, 14 (8.6%) were DNA positive, and of the 209 such subjects
for type 18, 14 (6.7%) were DNA positive (data not shown).
Immunogenicity Analyses
Per-protocol immunogenicity analysis results are shown in
Table 3. The seroconversion proportion was close to 100% for
HPV types 6, 11, and 16 in strata A and B, and for type 18, 91%
in stratum A and 85% in stratum B. In stratum C, the propor-
tion of responders was 84%, 92%, 93%, and 75% for types 6, 11,
16, and 18, respectively. For all 4 types in both strata A and B,
and for HPV types 6, 11, and 16 in stratum C, the lower bounds
of the CIs were >70%. The CI for type 18 in stratum C includes
70%. Week 28 serostatus among all study participants who re-
ceived at least 1 vaccine and were seronegative for the respective
HPV type at baseline, regardless of the number of vaccines
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received, was also analyzed, and the results were similar. Table 3
presents HPV antibody concentrations at week 28 in partici-
pants who were seronegative at baseline, and Table 4 presents
results in participants who were seropositive at baseline.
Predictors of Seroconversion
Week 28 seroconversion was compared pairwise among the 3
CD4 cell count strata on participants who received at least 1
vaccine and who were seronegative to at least 1 of the 4 HPV
Table 1. Baseline Characteristics
CD4 Stratum
Characteristic Total A (>350 Cells/µL) B (201–350 Cells/µL) C (≤200 Cells/µL)
No. of participants 315 127 95 93
Age, y, median (Q1, Q3) 36 (30, 41) 35 (29, 40) 38 (33, 42) 36 (31, 40)
Race/ethnicity
White non-Hispanic 11% 15% 9% 9%
Black non-Hispanic 56% 53% 62% 55%
Hispanic 31% 31% 26% 34%
Other/unknown 2% 1% 2% 2%
CD4, cells/µL, median (Q1, Q3) 310 (197, 498) 519 (418, 664) 287 (246, 344) 154 (86, 188)
Nadir CD4, cells/µL, median (Q1, Q3) 179 (47, 314) 368 (234, 482) 176 (64, 261) 41 (20, 108)
Undetectable plasma HIV-1 RNA 40% 38% 45% 38%
Detectable plasma HIV-1 RNAa 60% 62% 54% 62%
Missing <1% 0% 1% 0%
Plasma HIV-1 RNA
≤10 000 copies/mL 64% 56% 73% 66%
>10 000 copies/mL 36% 44% 26% 34%
Missing <1% 0% 1% 0%
Plasma HIV-1 RNA
≤400 copies/mL 50% 43% 58% 51%
>400 copies/mL 50% 57% 41% 49%
Missing <1% 0% 1% 0%
No antiretrovirals 34% 54% 25% 14%
Abbreviations: HIV-1, human immunodeficiency virus type 1; Q1, 1st quartile; Q3, 3rd quartile.
a Lower limit of quantitation of the HIV RNA assay is 1.4 log10 copies/mL.
Table 2. Baseline Seropositivity for Human Papillomavirus Vaccine Types
CD4 Stratum
HPV Type Total A (>350 Cells/µL) B (201–350 Cells/µL) C (≤200 Cells/µL)
No.a 308 120 95 93
Seropositivity for type 6 126 (41%) 54 (45%) 35 (37%) 37 (40%)
Seropositivity for type 11 64 (21%) 22 (18%) 23 (24%) 19 (20%)
Seropositivity for type 16 100 (32%) 44 (36%) 30 (32%) 26 (28%)
Seropositivity for type 18 61 (20%) 29 (24%) 12 (13%) 20 (21%)
Seronegative for all 4 types 121 (39%) 44 (37%) 42 (44%) 35 (38%)
Seropositive for any 1 type 86 (28%) 33 (27%) 24 (25%) 29 (31%)
Seropositive for any 2 types 53 (17%) 20 (17%) 15 (16%) 18 (19%)
Seropositive for any 3 types 35 (11%) 18 (15%) 10 (11%) 7 (7%)
Seropositive for all 4 types 13 (4%) 5 (4%) 4 (4%) 4 (4%)
Abbreviation: HPV, human papillomavirus.
a No. of participants with results for all 4 HPV vaccine types available.
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types at baseline. There was a numerical trend of lower serocon-
version in stratum C compared with stratum A (92% vs 98%,
P = .080) and compared with stratum B (92% vs 98%,
P = .096). Seroconversion proportions were too high for HPV
types 6, 11, and 16 in strata A and B to discern differences be-
tween HIV RNA groups. In stratum C, seroconversion
proportion for HPV types 6, 11, 16, and 18 were 89%, 97%,
100%, and 91%, respectively, among women with a viral load
<400 copies/mL compared with 73%, 77%, 81%, and 56%
among women with a viral load >400 copies/mL (P = .29, .01,
.01, and .001, respectively). Similar results were found for all
types using the viral cutoff of 10 000 copies/mL except for
HPV-16, for which the result was only statistically significant
when using the viral cutoff of 400 copies/mL. In the GEE
model, the odds of seroconversion in HPV types 6, 11, and
16 were higher compared with type 18, with corresponding
OR estimates of 3.45, 3.45, and 4.53 for types 6, 11, and 16
(P = .0005, .0001, and <.0001, respectively). The GEE model
also showed that seroconversion was higher with CD4 cell
count >200 µL (odds ratio [OR], 3.31; P = .01) and lower with
HIV RNA >10 000 copies/mL (OR, 0.26; P = .005). Age effect
was not statistically significant.
Safety Issues
There were no significant safety issues identified by the study
monitoring committee. There were 2 deaths, both from stra-
tum A (1 from lymphoma and 1 from meningitis), neither re-
lated to the vaccine. One participant in stratum B had an
allergic reaction; 1 participant from stratum C developed a
grade 3 fever. Sixteen participants had grade 1 or higher
fever reported during the postvaccination follow-up (n = 5, 4,
and 7 in strata A, B, and C, respectively). Three participants
from stratum C experienced grade 2 injection site reactions.
Overall, 17% of participants experienced grade 3 or higher ad-
verse events, 11% grade 3 or higher signs and symptoms, and
8% grade 3 or higher laboratory abnormalities. Laboratory ab-
normalities were more common in individuals who were more
immune compromised. The most common adverse event was
pain; other common events were neurological, gastrointestinal,
and skin related.
DISCUSSION
The quadrivalent HPV vaccine is safe and immunogenic among
HIV infected women aged 13–45 years who were seronegative
Table 3. Human Papillomavirus Antibody Concentrations at Week 28 in Participants Seronegative for a Given Type at Baseline
Participants Seronegative for HPV Type at Baseline











GMTs at Week 28,
mMU/mL (95% CI)
Median Titer at Week 28,
log10 mMU/mL (Q1, Q3)
Type 6
A 54 52 96.3 (87.3–99.5) 60 58 462 (321–667) 2.70 (2.37, 3.11)
B 50 50 100.0 (92.9–100.0) 58 57 349 (242–504) 2.50 (2.12, 2.96)
C 45 38 84.4 (70.5–93.5) 52 42 137 (82–229) 2.35 (1.41, 2.84)
Type 11
A 86 84 97.7 (91.9–99.7) 93 91 477 (362–627) 2.76 (2.41, 3.08)
B 59 58 98.3 (90.9–100.0) 70 67 417 (287–607) 2.64 (2.26, 3.05)
C 62 57 91.9 (82.2–97.3) 71 62 205 (129–327) 2.51 (1.79, 2.93)
Type 16
A 67 66 98.5 (92.0–100.0) 73 72 1200 (871–1654) 3.14 (2.80, 3.49)
B 56 55 98.2 (90.4–100.0) 63 61 1117 (746–1672) 3.12 (2.79, 3.46)
C 56 52 92.9 (82.7–98.0) 64 57 571 (328–994) 3.03 (2.26, 3.39)
Type 18
A 78 71 91.0 (82.4–96.3) 86 78 175 (126–243) 2.25 (2.01, 2.66)
B 71 60 84.5 (74.0–92.0) 80 66 171 (115–255) 2.34 (1.74, 2.82)
C 61 46 75.4 (62.7–85.5) 69 50 94 (59–149) 2.09 (1.15, 2.62)
Abbreviations: CI, confidence interval; GMT, geometric mean titer of HPV antibodies; HPV, human papillomavirus; mMU/mL, milli-Merck units/mL; Q1, 1st quartile;
Q3, 3rd quartile.
a Participants seronegative for a given type at baseline who completed the vaccination series per protocol with HPV antibody results at week 28 study visit.
b Participants who had HPV antibody results available at both baseline and week 28 study visits and who had received either partial or complete vaccination series.
c No. of participants in the analysis.
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for the HPV types included in the vaccine, with observed sero-
conversion proportions >75% for all 4 HPV types. For women
seropositive for the given HPV types prior to the vaccination
series, the vaccine induced a significant increase in antibody
levels.
Seroconversion proportions were higher among women
with baseline CD4 cell counts >200 cells/µL compared with
≤200 cells/µL. This is consistent with observations from immu-
nogenicity studies of other vaccines (eg, hepatitis A and B) but
is a new finding for the HPV vaccine. Prior immunogenicity
studies of the quadrivalent HPV vaccine among HIV- infected
men, children, and young women did not include participants
with low CD4 cell counts.
The effects of HIV RNA load on seroconversion were evalu-
ated. Among women with CD4 counts ≤200 cells/µL, women
with HIV RNA load <400 copies/mL at baseline had better
seroconversion proportions for HPV types 11, 16, and 18 com-
pared with women with viral loads ≥400 copies/mL. Women
with CD4 counts >200 cells/µL had seroconversion proportions
>90% for all HPV types, so we were unable to discern differenc-
es between HIV RNA groups, a finding similar to prior studies
of relatively immunocompetent HIV-infected men and young
women. We did not observe a relationship between age and se-
roconversion rates.
The odds of seroconversion were significantly higher for
HPV types 6, 11, and 16 compared with type 18 as measured
by cLIA. This finding is consistent with other studies and
may be related to the assay used and not due to an inherent dif-
ference in immunogenicity between HPV types [21–23]. The
cLIA is a type-specific assay that measures antibody binding
to a single epitope. Immunoglobulin G (IgG) LIA is an antibody
direct binding assay that measures all IgG with an increased
sensitivity over the cLIA [24]. Brown et al assessed the antibody
responses of young women to the quadrivalent HPV vaccine by
both assays on the same sera and found that after 4 years, the
seropositivity for HPV type 18 remained high at 97% when
measured by the total IgG LIA but declined to 65% using
cLIA and remained similar by both assays for HPV types 6,
11, and 16 [24]. The antibody concentrations or GMTs induced
by the quadrivalent HPV vaccine were significantly higher than
those induced by natural HPV infection. The GMT levels
among the women with CD4 cell counts >200 cells/µL were
similar to those found in HIV-infected men with comparable
CD4 cell counts. Among women with CD4 cell counts <200
cells/µL, however, we found a trend for lower titers compared
with higher CD4 cell counts, with a statistical significance
noted for only HPV-6. When compared with published data
on HIV-uninfected women, the anti–HPV-16 and -18 GMT
Table 4. Human Papillomavirus Antibody Concentrations at Week 28 in Participants Seropositive for a Given Type at Baseline




















Change in Titer, log10
mMU/mL (Q1, Q3)
Type 6
A 54 69 (55–87) 1.89 (1.54, 2.07) 52 770 (479–1238) 2.96 (2.53, 3.50) 1.12 (0.59, 1.54)
B 35 68 (50–91) 1.88 (1.45, 2.16) 33 651 (369–1151) 2.84 (2.55, 3.27) 1.10 (0.61, 1.52)
C 37 85 (66–109) 1.98 (1.63, 2.10) 36 725 (499–1055) 2.84 (2.51, 3.12) 0.97 (0.55, 1.29)
Type 11
A 22 67 (42–108) 1.75 (1.52, 2.05) 20 1253 (737–2131) 3.19 (2.75, 3.37) 1.32 (1.07, 1.71)
B 23 70 (43–115) 1.81 (1.45, 2.01) 21 951 (399–2268) 2.99 (2.42, 3.40) 1.42 (0.86, 1.59)
C 19 96 (46–200) 1.85 (1.38, 2.61) 17 704 (407–1217) 3.00 (2.59, 3.11) 0.60 (0.28, 1.25)
Type 16
A 44 91 (66–127) 1.85 (1.59, 2.29) 40 3027 (1920–4771) 3.56 (3.31, 3.83) 1.65 (1.26, 1.93)
B 30 136 (74–249) 1.88 (1.52, 2.76) 28 2208 (1037–4702) 3.59 (2.91, 3.80) 1.29 (0.84, 1.86)
C 26 83 (43–160) 1.67 (1.46, 2.09) 24 1252 (685–2287) 3.04 (2.65, 3.53) 1.06 (0.62, 1.79)
Type 18
A 29 68 (49–95) 1.72 (1.56, 2.05) 27 771 (403–1475) 3.02 (2.37, 3.46) 1.02 (0.48, 1.51)
B 12 93 (41–212) 1.82 (1.51, 2.22) 11 487 (166–1424) 2.74 (2.12, 3.09) 0.89 (0.50, 1.53)
C 20 85 (54–132) 1.88 (1.60, 2.15) 19 458 (250–838) 2.66 (2.18, 3.02) 0.85 (0.04, 1.22)
Abbreviations: CI, confidence interval; GMT, geometric mean titer of HPV antibodies; HPV, human papillomavirus; ITT, intention-to-treat; mMU/mL, milli-Merck units/
mL; Q1, 1st quartile; Q3, 3rd quartile.
a No. of participants in the analysis.
b Participants who received any vaccines with HPV antibody results at both baseline and week 28 study visits.
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in our HIV-infected cohort was almost half that of HIV unin-
fected women in similar age groups (GMT range, 571–1200
mMU/mL for HPV-16 in our study vs 2134 mMU/mL in the
literature) [25]. The clinical significance of this finding is un-
clear as the protective titers of HPV antibodies are not defined.
Our definition of seroconversion is likely to be higher than the
titers required for clinical protection.
The quadrivalent HPV vaccine has been shown to be highly
effective in preventing HPV acquisition and disease due to the
vaccine types in healthy women, especially if administered prior
to HPV exposure. In the current study, only 4% of women were
seropositive for all 4 vaccine types, either due to lack of prior
HPV exposure or due to loss of serum HPV antibodies. This
suggests that the majority of HIV-infected women, regardless
of immune status, would benefit from the vaccination series. Fu-
ture studies are needed to determine the duration of immuno-
genicity as well as an assessment of the effect of anogenital and
oral HPV infection on vaccine responses.
In conclusion, data from this multicenter study show that the
quadrivalent HPV vaccine directed against HPV types 6, 11, 16,
and 18 is safe and immunogenic in HIV-infected women aged
13–45 years supporting the recommendations of the Advisory
Committee on Immunization Practices and the World Health
Organization to vaccinate HIV-infected persons. Women with
HIV RNA load >10 000 copies/mL and/or CD4 count <200
cells/µL had lower seroconversion, and there was a tendency
for lower HPV titers in the more immunosuppressed group of
vaccinated women.
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